Search
Futibatinib
go.drugbank.com/drugs/DB15149ApprovedInvestigationalFutibatinib is an inhibitor of Fibroblast Growth Factor receptor (FGFR), which comprises a group of receptor tyrosine kinases that play a key role in cell proliferation, differentiation, migration, and survival. FGFR was investigated in ...
Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitorsAvapritinib
go.drugbank.com/drugs/DB15233ApprovedInvestigationalAvapritinib, or BLU-285, is a selective tyrosine kinase inhibitor of KIT and platelet derived growth factor receptor alpha indicated for the treatment of unresectable, metastatic gastrointestinal stromal tumors and advanced systemic mast...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesElexacaftor
go.drugbank.com/drugs/DB15444ApprovedInvestigationalElexacaftor (previously VX-445) is a small molecule, next-generation corrector of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. It received FDA approval in October 2019 in combination with tezacaftor and ivacaft...
Categories: Cytochrome P-450 CYP1A2 Inhibitors, P-glycoprotein inhibitorsZuranolone
go.drugbank.com/drugs/DB15490ApprovedInvestigationalZuranolone is a neuroactive steroid that acts as a positive allosteric modulator of the GABAA receptors. Unlike other more common GABAA positive allosteric modulators on the market like benzodiazepines, zuranolone can modulate both synap...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesPradefovir
go.drugbank.com/drugs/DB15550InvestigationalPradefovir is a prodrug of adefovir.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesDesfesoterodine
go.drugbank.com/drugs/DB15578InvestigationalDesfesoterodine is a metabolite of tolterodine.
Categories: Cytochrome P-450 CYP2D6 Substrates, Cytochrome P-450 SubstratesCryptotanshinone
go.drugbank.com/drugs/DB15579ExperimentalCategories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP2C9 InhibitorsJPC-3210
go.drugbank.com/drugs/DB15609ExperimentalJPC-3210 is a potent antimalarial agent. It is an erythrocytic schizonticide with potent in vitro antimalarial activity against multidrug-resistant Plasmodium falciparum lines, low cytotoxicity, potent in vivo efficacy against murine mal...
Categories: Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP3A InhibitorsBrensocatib
go.drugbank.com/drugs/DB15638ApprovedNon-cystic fibrosis bronchiectasis (NCFB) is a chronic lung disease characterized by airway widening, mucus accumulation, and neutrophilic inflammation. Brensocatib is a first-in-class dipeptidyl peptidase 1 (DPP1) inhibitor that inhibit...
Categories: Cytochrome P-450 CYP2C8 Substrates, Cytochrome P-450 CYP3A InducersPralsetinib
go.drugbank.com/drugs/DB15822ApprovedInvestigationalPralsetinib, similar to the previously approved selpercatinib, is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes. Enhanced RET (Rearranged during transfection) oncogene expres...
Categories: Cytochrome P-450 CYP2C8 Inducers, Cytochrome P-450 CYP1A2 Substrates